OMX Ventures

Constructive Bio is a biotechnology company focused on genome rewriting to advance bioprocesses and biopharmaceuticals. By transforming living cells into biofactories, it aims to develop sustainable materials and therapeutics. The company possesses the capability to create virus-resistant organisms and utilizes its proprietary technology to biosynthesize various classes of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram the genetic code, enabling the production of natural molecules and exploring chemical spaces that are not accessible through traditional biological methods. Constructive Bio's work positions it at the forefront of biotechnology, paving the way for the next generation of sustainable solutions in the life sciences sector.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the obstacles posed by tumors. Through its innovative approach, OverT Bio aims to enhance the effectiveness and durability of immunotherapies, contributing to advancements in cancer identification and treatment within the healthcare sector.

Tagomics is a company focused on enhancing disease diagnosis through advanced multitopic profiling and epigenetic-based chemical modifications. By leveraging epigenetics, Tagomics aims to provide a deeper understanding of biological processes by adding an additional layer of information to the genetic code. This approach allows for the discovery of dynamic and sensitive biomarkers that can reflect the influence of lifestyle, environmental factors, and disease progression. The company's innovations are particularly aimed at early detection of colorectal and other common cancers, promoting cost-effective and efficient epigenetic biomarker discovery. Through its work, Tagomics is transforming the landscape of disease diagnosis and patient care.

Freya Biosciences is a clinical-stage women's health company headquartered in Copenhagen and Boston, specializing in the development of microbial immunotherapies. The company focuses on addressing significant unmet medical needs across various indications by utilizing a proprietary platform to engineer and manufacture live microbes. These engineered microbes are designed to be both safe and effective for human use, facilitating the creation of innovative treatments for a range of diseases.

Aperiam Bio, founded in 2021 and based in Austin, Texas, specializes in the development of industrial and therapeutic proteins. The company collaborates with enzyme engineers and distributors to produce stabilized, solubilized, and catalytically optimized proteins. Utilizing advanced deep learning optimization and proprietary algorithms, Aperiam Bio identifies critical components of protein chemistry to discover novel gain-of-function mutations. This innovative approach allows the engineering of biological molecules aimed at enhancing agricultural and pharmaceutical applications. By focusing on hyper-folded proteins, Aperiam Bio enables researchers to create more effective and durable proteins than those found in nature, ultimately contributing to advancements in various fields and improving lives.

VedaBio is a developer of advanced molecular diagnostics equipment that focuses on enhancing the accuracy and efficiency of point-of-care testing. The company's innovative platform enables near-instant molecular detection of highly multiplexed analytes, achieving performance comparable to traditional polymerase chain reaction (PCR) methods without the need for target amplification. By streamlining complex testing processes, VedaBio aims to provide medical researchers and healthcare professionals with reliable and cost-effective solutions for antigen testing, ultimately transforming the landscape of molecular biology and diagnostics.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

Constructive Bio is a biotechnology company focused on genome rewriting to advance bioprocesses and biopharmaceuticals. By transforming living cells into biofactories, it aims to develop sustainable materials and therapeutics. The company possesses the capability to create virus-resistant organisms and utilizes its proprietary technology to biosynthesize various classes of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram the genetic code, enabling the production of natural molecules and exploring chemical spaces that are not accessible through traditional biological methods. Constructive Bio's work positions it at the forefront of biotechnology, paving the way for the next generation of sustainable solutions in the life sciences sector.

Replay is a genome writing company focused on advancing genomic medicine by reprogramming biological systems through the synthesis and delivery of large DNA constructs. The company aims to harness the potential of genome engineering to create innovative solutions in medicine, enhancing the ability to manipulate genetic material for therapeutic purposes. By developing technologies that enable precise DNA writing, Replay seeks to redefine the landscape of genetic research and its applications, ultimately contributing to improved health outcomes and the treatment of various diseases.

1859, Inc. is a biotechnology company established in 2019 and based in San Diego, California. The company specializes in the discovery and development of next-generation therapeutics, utilizing an advanced artificial intelligence-powered drug discovery platform. This innovative platform integrates combinatorial chemistry, pico-scale activity-based screening, and artificial intelligence to generate millions of empirical data points. By doing so, 1859 aims to accelerate the process of discovering novel small molecule therapeutics, thereby enhancing the capabilities of pharmaceutical companies in developing new medicines.

Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatments through innovative therapies. The company specializes in the development of antibody-drug conjugates (ADCs), utilizing a unique protein engineering approach that enhances the effectiveness of these targeted therapies. Mythic Therapeutics' technology significantly improves the uptake of therapeutic agents in cancerous cells while minimizing their release in healthy cells, thereby increasing efficacy across various cancer types. This method not only boosts the potency of the treatments but also ensures a favorable safety profile, enabling healthcare providers to harness the full potential of ADCs. As such, Mythic Therapeutics aims to make a meaningful impact on cancer care by addressing a broad spectrum of tumor targets.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Sestina Bio, LLC, established in 2020 and headquartered in Delaware, is a biotechnology company dedicated to addressing global challenges through innovative synthetic biology solutions. The company's mission is to create an advanced research and development platform that integrates cutting-edge technologies such as synthetic biology, data sciences, and bio-analytical systems. Sestina Bio specializes in engineering yeast and bacteria to produce chemicals and pharmaceuticals using its proprietary genome editing tools, single-cell biology techniques, and machine learning algorithms.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

TARA Biosystems, Inc. is a biotechnology company that specializes in developing organ-on-a-chip technology for evaluating new therapies and drug compounds, particularly in the field of cardiac medicine. Founded in 2014 and based in the United States, the company produces predictive in vitro human cardiac tissue models derived from human stem cells. These models are matured to physiologically relevant adult-like levels, allowing for accurate measurement of cardiac functionality, including contractile force. TARA Biosystems focuses on enhancing drug discovery and safety assessment processes by providing high-fidelity solutions that enable faster and safer development of new medicines. By harnessing human biology and data, the company aims to transform cardiac drug discovery and improve patient health outcomes.

Matterworks is a developer of an artificial intelligence platform focused on advancing the field of metabolomics within the life sciences. The company's technology enhances analytical capabilities, allowing scientific researchers to conduct faster and more comprehensive metabolomic screenings. By facilitating the discovery and engineering processes, Matterworks aims to accelerate scientific progress and support innovation in various biological applications.